Shupo, Francis http://orcid.org/0000-0001-5063-574X
Abrams, Keith R. http://orcid.org/0000-0002-7557-1567
Ademi, Zanfina http://orcid.org/0000-0002-0625-3522
Wayi-Wayi, Grace
Zibelnik, Natasa
Kirchmann, Matt http://orcid.org/0000-0003-1272-1326
Rutherford, Carolyn http://orcid.org/0000-0002-3103-7776
Makarounas-Kirchmann, Kelly http://orcid.org/0000-0003-4393-4199
Funding for this research was provided by:
EUSA Pharma
Article History
Accepted: 21 May 2023
First Online: 12 June 2023
Declarations
:
: EUSA Pharma UK (LTD.) funded the work taken to write this manuscript.
: Francis Shupo, Grace Wayi-wayi and Natasa Zibelnik were employees of EUSA Pharma UK (LTD.) at the time of conducting this study. EUSA Pharma UK (LTD.) provided funding to KMC Health Care to support the work of Matt Kirchmann (Director), Carolyn Rutherford (Senior Health Economist) and Kelly Makarounas-Kirchmann (Principal) in undertaking the health technology assessment of Siltuximab. Zanfina Ademi reviewed the model and received no payment for this. EUSA Pharma UK (LTD.) also provided funding to Visible Analytics Limited for the work of Keith R Abrams (Director and Partner) in undertaking the Health Technology Assessment of Siltuximab.
: The datasets and code generated and/or analysed during the current study are available from the corresponding author on reasonable request.
: Studies MCD2001 (NCT01024036) and MCD2002 (NCT01400503) had received relevant ethics approvals. Ethics approval was not needed for the cost-effectiveness analysis, as it was based on existing and published data.
: The cost-effectiveness data were based on existing published data, and there was no need for consent.
: The cost-effectiveness data were based on existing published data, and there was no need for consent.
: All authors contributed to the study conception and design. Zanfina Ademi and Keith R Abrams independently assessed the structural validity and internal consistency of the model. Material preparation, data collection and analysis were performed by Kelly Makarounas-Kirchmann, Matt Kirchmann, Carolyn Rutherford and Przemyslaw Holko. The first draft of the manuscript was primarily written by Francis Shup, Grace Wayi-Wayi and Kelly Makarounas-Kirchmann, and all authors provided comment and revision on subsequent versions of the manuscript. All authors read and approved the final manuscript.